American College Of Cardiology Highlights
Plavix/aspirin combo benefit?: Adding clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis' Plavix) to a regimen of standard, low-dose aspirin did not significantly reduce the combined rate of death, heart attack or stroke in the 15,603-patient Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. In the overall population, clopidogrel plus aspirin had no significant impact on outcomes after a median follow-up of 28 months. In the placebo plus aspirin group, the combined rate of cardiovascular death, heart attack or stroke was 7.3% compared to 6.8% in the clopidogrel plus aspirin group. However, when the analysis focused on the 12,153 patients with established cardiovascular disease, adding clopidogrel cut the combined rate to 6.9% from 7.9% - a statistically significant difference. Plavix is labeled for early and long-term risk reduction in patients at risk for atherothrombotic events...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth